A型肉毒毒素局部注射治疗结缔组织病相关雷诺现象的疗效观察

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (2777 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究A型肉毒毒素（botulinum neurotoxin type A,BTX-A）局部注射治疗结缔组织病相关雷诺现象（Raynaud's phenomenon,RP）的临床疗效。方法: 纳入双手基线数据无差异的受试者,随机选择受试者的一只手为注射侧,于手指周围神经血管束分叉区域注射BTX-A,另一只手为对照侧,随访记录0、2、8、12周时视觉模拟疼痛量表（visual analogue pain scale,VAS）评分、雷诺评分（Raynaud's score,RS）、溃疡评分（ulcer score,US）、平均指端皮肤温度、平均毛细血管充盈时间和不良反应发生情况,应用SPSS 25.0软件进行统计分析。结果: 27例患者完成治疗和随访,治疗2、8、12周后,注射侧与对照侧对比VAS评分总体均数有统计学差异。治疗8、12周后,注射侧与对照侧对比雷诺评分总体均数有统计学差异。2周时两侧雷诺评分及2、8、12周时两侧溃疡评分,平均指端皮肤温度、平均经皮氧饱和等相比总体均属无统计学差异。治疗2、8、12周与治疗前的VAS评分对比差异均有统计学意义,治疗8、12周雷诺评分治疗前对比差异均有统计学意义,治疗8、12周溃疡评分治疗前对比差异均有统计学意义,余观察指标治疗前后对比差异均无统计学意义。结论: 局部注射A型肉毒毒素能改善雷诺患者的疼痛,减少雷诺现象发生的频率、促进溃疡愈合且不良反应少,是一种安全有效且简便易行的方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘兴林
	张昊
	韦翠娥
	李明

关键词 ： A型肉毒毒素, 结缔组织病, 雷诺现象, 手指缺血, 手指缺血性溃疡

Abstract：Objective To investigate the clinical efficacy and safety of botulinum neurotoxin type A (BTX-A) local injection in the treatment of Raynaud's phenomenon (RP) associated with connective tissue disease. Methods Subjects with no difference in baseline data of both hands were included. Subjects were randomly selected to inject BTX-A in the area of bifurcation of neurovascular bundle around fingers with one hand as the injection side and the other hand as the control side. Visual analogue pain scale (VAS) scores, Raynaud's score (RS) and ulcer score (RS) were recorded at 0, 2, 8 and 12 weeks score, US), average fingertip skin temperature, average capillary filling time and occurrence of adverse reactions were statistically analyzed by SPSS 25.0 software. Results 27 patients completed treatment and follow-up. After 2, 8, and 12 weeks of treatment, there was a statistical difference in the overall mean VAS score between the injection side and the control side. After 8, 12 weeks of treatment, there was a statistically significant difference in the mean Reynolds score between the injection side and the control side. There were no significant differences in Reynolds score at 2 weeks, ulcer score at 2, 8 and 12 weeks, average fingerend skin temperature and average percutaneous oxygen saturation. VAS scores at 2, 8 and 12 weeks of treatment were statistically significant compared with those before treatment, Raynaud scores at 8 and 12 weeks of treatment were statistically significant compared with those before treatment, ulcer scores at 8 and 12 weeks of treatment were statistically significant compared with those before treatment, there was no significant difference in the remaining observation indicators before and after treatment. Conclusion Local injection of botulinum toxin type A can improve the pain of patients with Raynaud, reduce the frequency of Raynaud phenomenon, promote ulcer healing with less adverse reactions, and is a safe, effective, simple and feasible method.

Key words： botulinum toxin A connective tissue disease Reynaud's phenomenon finger ischemia finger ischemic ulcer

收稿日期: 2023-08-30

中图分类号:

R593.2

基金资助:山东省中医药科技发展计划项目“玉屏风颗粒对系统性红斑狼疮发生反复感冒影响评价的临床研究”（2019-0712）

通讯作者: 李明,E-mail：15826691869@163.com

引用本文:

刘兴林, 张昊, 韦翠娥, 李明. A型肉毒毒素局部注射治疗结缔组织病相关雷诺现象的疗效观察[J]. 湖南师范大学学报(医学版), 2024, 21(2): 56-60. LIU Xinglin, ZHANG Hao, WEI Cui'e, LI Ming. Botulinum toxin A in the local injection treatment of Raynaud phenomenon in connective tissue disease and efficacy observation. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(2): 56-60.

链接本文:

http://yxb.hunnu.edu.cn/CN/ 或 http://yxb.hunnu.edu.cn/CN/Y2024/V21/I2/56

[1] 罗靓, 蔡青猛, 刘香君, 等. 以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素[J]. 北京大学学报 (医学版), 2022, 54(06): 1224-1228.
[2] 姚宏凯, 刘迎, 靳令经. A型肉毒毒素改善雷诺现象血管痉挛的作用及机制研究进展[J]. 国际神经病学神经外科学杂志, 2020, 47(06): 641-644.
[3] 吴丹, 荣晓凤. 雷诺综合征的中西医诊治研究进展[J]. 现代中西医结合杂志, 2021, 30(30): 3415-3420.
[4] 戴翔, 刘彦国, 王俊. 胸腔镜下交感神经切断术治疗雷诺综合征新进展[J]. 中华胸心血管外科杂志, 2018, 34(9): 565-567.
[5] 王远卓, 郑清月, 张翰林, 等. A型肉毒毒素治疗雷诺现象的研究进展[J]. 基础医学与临床, 2022, 42(10): 1611-1615.
[6] WINTER AR, CAMARGO MACIAS K, KIM S, et al.The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud＇s Phenomenon: A Case Series[J]. Cureus, 2020, 12(5): 8235.
[7] HABIB SM, BRENNINKMEIJER EEA, VERMEER MH, et al.Botulinum toxin type A in the treatment of Raynaud's phenomenon[J]. Dermatol Ther, 2020, 33(6): e14182.
[8] QUINTANA CASTANEDO L, FEITO RODRÍGUEZ M, MASEDA PEDRERO R, et al. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin[J]. Pediatr Dermatol, 2020, 37(4): 681-683.
[9] DHALIWAL K, GRIFFIN MF, SALINAS S, et al.Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series[J]. Clin Rheumatol, 2019, 38(12): 3669-3676.
[10] MEDINA S, GÓMEZ-ZUBIAUR A, VALDEOLIVAS-CASILLAS N, et al. Botulinum toxin type A in the treatment of Raynaud＇s phenomenon: A three-year follow-up study[J]. Eur J Rheumatol, 2018, 5(4): 224-229.
[11] NAGARAJAN M, MCARTHUR P.Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience[J]. Rheumatol Int, 2021, 41(5): 943-949.
[12] MERKEL P A, HERLYN K, MARTIN R W, et al.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon[J]. Arthritis Rheum, 2002, 46(9): 2410-2420.
[13] 周末. A型肉毒毒素治疗系统性硬化症继发雷诺现象的疗效及皮肤镜评估[D]. 北京协和医学院, 2017.
[14] SEYEDMARDANI SM, AGHDASHI MA, SOLTANI S, et al. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients[J]. Curr Rheumatol Rev, 2022, 18, (1): 48-57.
[15] GOLDBERG SH, AKOON A, KIRCHNER HL, et al. The Effects of Botulinum Toxin A on Pain in Ischemic Vasospasm[J]. J Hand Surg Am, 2021, 46(6): 513. e1-513. e12.
[16] UPPAL L, DHALIWAL K, BUTLER PE.A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma[J]. J Hand Surg Eur Vol, 2014, 39(8): 876-880.
[17] JOKAR MH, BAGHBANI B, GERAYLOW KR, et al.Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis[J]. Reumatologia, 2022, 60(6): 392-398.
[18] SENET P, MAILLARD H, DIOT E, et al.Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study[J]. Arthritis Rheumatol, 2023, 75(3): 459-467.
[19] BELLO RJ, COONEY CM, MELAMED E, et al.The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial[J]. Arthritis Rheumatol, 2017, 69(8): 1661-1669.
[20] JENKINS SN, NEYMAN KM, VELEDAR E, et al.A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon[J]. J Am Acad Dermatol, 2013, 69(5): 834-835.